Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04655313 · ClinicalTrials.gov registry record · Phase 2
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)
A Phase 2 study, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT04655313 is a Phase 2 study that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 20 participants.
The verdict
NCT04655313, a Phase 2 study, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 6 to 11 years old) with plaque psoriasis:
Interventions
- DRUG ARQ-151 cream 0.3%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-11-30 |
| Est. Completion | 2022-01-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04655313
The ClinicalTrials.gov registry entry for NCT04655313 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARQ-151 cream 0.3% is the first listed.
NCT04655313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04655313 about?
NCT04655313 is a clinical study titled "Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)". This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 6 to 11 years old) with plaque psoriasis:
What is the current status of trial NCT04655313?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2020-11-30. Estimated completion is 2022-01-12.
What interventions are being tested in trial NCT04655313?
The interventions under investigation include: ARQ-151 cream 0.3% (DRUG).
Who is sponsoring clinical trial NCT04655313?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.